Literature DB >> 20435837

Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Charles R Harper1, Terry A Jacobson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20435837      PMCID： PMC2861973          DOI： 10.4065/mcp.2009.0517

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  32 in total

Review 1.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2008-04-15       Impact factor: 24.094

2.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

Review 3.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Authors:  Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2009-10       Impact factor: 5.223

4.  The importance of non-HDL cholesterol reporting in lipid management.

Authors:  Michael J Blaha; Roger S Blumenthal; Eliot A Brinton; Terry A Jacobson
Journal:  J Clin Lipidol       Date:  2008-06-28       Impact factor: 4.766

Review 5.  Metabolic origins and clinical significance of LDL heterogeneity.

Authors:  Kaspar K Berneis; Ronald M Krauss
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

6.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

7.  Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Authors:  John J P Kastelein; Wim A van der Steeg; Ingar Holme; Michael Gaffney; Nilo B Cater; Philip Barter; Prakash Deedwania; Anders G Olsson; S Matthijs Boekholdt; David A Demicco; Michael Szarek; John C LaRosa; Terje R Pedersen; Scott M Grundy
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

8.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Authors:  P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

9.  Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation.

Authors:  M J Chapman; P M Laplaud; G Luc; P Forgez; E Bruckert; S Goulinet; D Lagrange
Journal:  J Lipid Res       Date:  1988-04       Impact factor: 5.922

10.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Authors:  John H Contois; Joseph P McConnell; Amar A Sethi; Gyorgy Csako; Sridevi Devaraj; Daniel M Hoefner; G Russell Warnick
Journal:  Clin Chem       Date:  2009-01-23       Impact factor: 8.327
View more
  13 in total

1.  Using apolipoprotein B to manage dyslipidemia.

Authors:  Jennifer G Robinson
Journal:  Mayo Clin Proc       Date:  2010-08       Impact factor: 7.616

2.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

3.  To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?

Authors:  Carl J Lavie; Richard V Milani; James H O'Keefe
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

4.  Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

Authors:  Safi U Khan; Muhammad U Khan; Shahul Valavoor; Muhammad Shahzeb Khan; Victor Okunrintemi; Mamas A Mamas; Thorsten M Leucker; Michael J Blaha; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-09-02       Impact factor: 7.804

5.  Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients.

Authors:  Min Ye; Yanqiu Liu; Haoyu Wang; Na Tian; Wei Li; Wei He; Hong Lin; Rui Fan; Cuiling Li; Donghong Liu; Fengjuan Yao
Journal:  Int Urol Nephrol       Date:  2017-11-10       Impact factor: 2.370

Review 6.  Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

7.  Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population.

Authors:  Anjali Manocha; Seema Bhargava; Rajneesh Jain; Mamta Kankra; Parul Singla; Parul Chugh
Journal:  Indian J Clin Biochem       Date:  2018-05-08

8.  Association of Spicy Food Consumption Frequency with Serum Lipid Profiles in Older People in China.

Authors:  K Yu; Y Xue; T He; L Guan; A Zhao; Y Zhang
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

9.  Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial.

Authors:  Christoph Höchsmann; James L Dorling; Corby K Martin; Robert L Newton; John W Apolzan; Candice A Myers; Kara D Denstel; Emily F Mire; William D Johnson; Dachuan Zhang; Connie L Arnold; Terry C Davis; Vivian Fonseca; Carl J Lavie; Eboni G Price-Haywood; Peter T Katzmarzyk
Journal:  Circulation       Date:  2021-02-09       Impact factor: 29.690

10.  Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008.

Authors:  Earl S Ford; Chaoyang Li; Allan Sniderman
Journal:  Cardiovasc Diabetol       Date:  2013-01-30       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.